Idexx Laboratories Inc
Q2 2023 Earnings
Market Reaction
S&P 500 over the same 30 days: −1.34%.
Did IDXX Beat Earnings? Q2 2023 Results
IDEXX Laboratories posted a convincing second-quarter beat, with earnings per share of $2.67 topping the $2.47 consensus estimate by 8.10% and revenue of $943.63 million edging ahead of the $934.42 million consensus by 0.99%, marking 9.7% growth from the year-ago period. The standout driver behind the quarter's profitability was a sharp pullback in research and development spending, which fell to just 4.9% of revenue compared to 14.3% in Q2 2022, lifting operating margin to 31.4% and contributing meaningfully to the EPS expansion. Growth was anchored by the Companion Animal Group, where diagnostics recurring revenue climbed 11% as reported and VetLab consumables delivered 14% reported growth, supported by stronger net pricing and a growing premium instrument installed base. Building on the momentum, IDEXX raised its full-year 2023 revenue outlook to $3.66 billion to $3.71 billion and lifted its EPS guidance to $9.64 to $9.90, reflecting 20% to 23% reported growth for the year.
- CAG Diagnostics recurring revenue growth of 11% reported and 12% organic driven by double-digit organic growth in U.S. and international regions
- Record second quarter global premium instrument placements supporting 11% annual installed base growth
- Higher net price realization across testing modalities
- Strong demand for cloud-based veterinary software solutions
- U.S. CAG Diagnostics organic recurring revenue growth premium of ~1,370 basis points over same-store clinical visit growth
- Gross margin expansion from net price gains, lab productivity, and operational initiatives
- Operating expense decline of 17% largely from lapping prior year discrete R&D investments
“Strong execution by IDEXX commercial and operational teams drove excellent growth results and financial performance in the second quarter. Our customers' increasing embrace of IDEXX innovations, including cloud-based software services, helps them address the growing global demand for pet healthcare by improving efficiency while maintaining quality of care and supporting veterinary teams. We are proud of our progress in advancing our business strategy, aligned with our purpose to create long-term value for our customers, employees, and shareholders by enhancing the health and well-being of pets, people, and livestock.”
IDEXX Laboratories CEO, on the earnings call
Forward Guidance & Outlook
IDEXX updated its full year 2023 revenue guidance to $3,660 million–$3,715 million, reflecting 8.5%–10% growth as reported and organically, driven by projected CAG Diagnostics recurring revenue growth of 10%–11%. The company raised its 2023 EPS outlook to $9.64–$9.90, representing 20%–23% reported growth and 24%–27% comparable growth, including approximately 12% combined EPS growth benefit from a Q1 2023 customer contract resolution payment and lapping of discrete 2022 R&D investments. Operating margin is projected at 29.3%–29.7% for the full year, with approximately 60 basis points of unfavorable net margin impact from foreign currency changes. Capital expenditures are expected to be approximately $180 million. Free cash flow is projected at 80%–90% of net income, and operating cash flow at 100%–110% of net income. Full year negative FX impact on EPS is estimated at $0.21.
IDXX YoY Financials
IDXX Revenue by Segment
IDXX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.